Summit Therapeutics Inc vs Zoetis Inc — how do they compare? Summit Therapeutics Inc trades at $14.57 (market cap $10.48B), while Zoetis Inc trades at $76.07 (market cap $31.95B). The key difference: Zoetis Inc is far larger — about 3× Summit Therapeutics Inc's market cap, and Zoetis Inc pays a 2.78% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SMMT | ZTS | |
|---|---|---|
Market Cap | $10.48B | $31.95B |
Sector | Health | Health |
52-Week High | $29.32 | $156.76 |
52-Week Low | $13.05 | $71.91 |
Enterprise Value | $9.90B | $39.24B |
Dividend Yield | — | 2.78% |
Trailing returns across standard periods
Latest headlines on both assets
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →